Rajendra Bahadur Shahi

Rajendra Bahadur Shahi PhD is a researcher at the Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), located at Pleinlaan 2, 1050 Brussel, Belgium. With an active research career spanning from 2012 to the present, he has established himself as a significant contributor to cancer genetics research with 11 research outputs documented in institutional records and an h-index reflecting substantial scholarly impact.

Dr. Shahi's research primarily focuses on cancer genetics, particularly in the areas of breast and lung cancer predisposition. His work centers on identifying genetic variants that predispose individuals to cancer, with special attention to BRCA1/2-negative familial cases. Using advanced genomic techniques like whole-exome sequencing and next-generation sequencing (NGS), he investigates cancer-associated genes and their mutations to better understand hereditary cancer syndromes and develop improved diagnostic approaches.

Analysis of Dr. Shahi's publication record reveals a clear progression from methodological development in NGS approaches toward increasingly sophisticated applications in clinical oncology. His research has evolved from foundational work on sequencing technologies to direct clinical applications in cancer predisposition and targeted therapies, particularly in breast and lung cancer. The integration of genomic data with clinical phenotypes represents a consistent theme throughout his scholarly output.

• European Association for Cancer Research (EACR) travel fellowship (2012)
• Organization of the European Cancer Institute (OECI) award (2013)
• Organization of the European Cancer Institute's (OECI) Award (2011)
• PhD Scholarship (2011)
• Prijs Kankeronderzoek (2016)

Dr. Shahi has been actively involved in presenting his research at numerous international conferences and workshops, demonstrating his commitment to advancing knowledge in cancer genomics. His scholarly work has garnered attention across multiple platforms, with significant readership on Mendeley and coverage in news outlets, indicating the relevance and impact of his research. He has also contributed to datasets that support reproducible research in cancer genetics.

Through his presentations and publications, Dr. Shahi has established himself as a contributor to the cancer research community, particularly in the application of genomic technologies to understand hereditary cancer predisposition. His work bridges basic genomic research with clinical applications, focusing on translating genetic findings into improved cancer risk assessment and potential therapeutic strategies.